Postbiotics: what else?

被引:254
作者
Tsilingiri, K. [1 ]
Rescigno, M. [1 ]
机构
[1] Ist Europeo Oncol, Dept Expt Oncol, I-20139 Milan, Italy
关键词
probiotics; postbiotics; inflammatory bowel disease; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; LACTOBACILLUS-SALIVARIUS; INTESTINAL MICROBIOTA; INFLAMMATORY DISEASE; EPITHELIAL-CELLS; CONTROLLED-TRIAL; DENDRITIC CELLS; INNATE IMMUNITY; DOUBLE-BLIND; IN-VITRO;
D O I
10.3920/BM2012.0046
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The use of probiotics and synbiotics in the food industry or as food supplements for a balanced diet and improved gut homeostasis has been blooming for the past decade. As feedback from healthy consumers is rather enthusiastic, a lot of effort is currently directed in elucidating the mechanisms of interaction between beneficial microbes and barrier and immune function of the host. The use of probiotics or synbiotics for treating certain pathologies has also been examined, however, the outcome has not always been favourable. In most cases, the effect of the administered probiotic is evident when the bacteria are still alive at the time they reach the small and large intestine, suggesting that it is dependent on the metabolic activity of the bacteria. Indeed, in some occasions it has been shown that the culture supernatant of these bacteria mediates the immunomodulatory effect conferred to the host. Recent work on relevant probiotic strains has also led to the isolation and characterisation of certain probiotic-produced, soluble factors, here called postbiotics, which were sufficient to elicit the desired response. Here, we summarise these recent findings and propose the use of purified and well characterised postbiotic components as a safer alternative for clinical applications, especially in chronic inflammatory conditions like inflammatory bowel disease, where probiotics have not yet given encouraging results as far as induction of remission is concerned.
引用
收藏
页码:101 / 107
页数:7
相关论文
共 51 条
[21]   Lactobacillus reuteri-produced cyclic dipeptides quench agr-mediated expression of toxic shock syndrome toxin-1 in staphylococci [J].
Li, Jingru ;
Wang, Wenliang ;
Xu, Stacey X. ;
Magarvey, Nathan A. ;
McCormick, John K. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (08) :3360-3365
[22]   A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial [J].
Ligaarden, Solveig C. ;
Axelsson, Lars ;
Naterstad, Kristine ;
Lydersen, Stian ;
Farup, Per G. .
BMC GASTROENTEROLOGY, 2010, 10 :X
[23]   Role of the Commensal Microbiota in Normal and Pathogenic Host Immune Responses [J].
Littman, Dan R. ;
Pamer, Eric G. .
CELL HOST & MICROBE, 2011, 10 (04) :311-323
[24]   Probiotics inhibit enteropathogenic E-coli adherence in vitro by inducing intestinal mucin gene expression [J].
Mack, DR ;
Michail, S ;
Wei, S ;
McDougall, L ;
Hollingsworth, MA .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1999, 276 (04) :G941-G950
[25]   A microbial symbiosis factor prevents intestinal inflammatory disease [J].
Mazmanian, Sarkis K. ;
Round, June L. ;
Kasper, Dennis L. .
NATURE, 2008, 453 (7195) :620-625
[26]   Probiotics in the Treatment of Human Inflammatory Bowel Diseases Update 2011 [J].
Meijer, Bartolomeus Joannes ;
Dieleman, Levinus Albert .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2011, 45 :S139-S144
[27]   Bifidobacterium breve and Streptococcus thermophilus secretion products enhance T helper 1 immune response and intestinal barrier in mice [J].
Ménard, S ;
Laharie, D ;
Asensio, C ;
Vidal-Martinez, T ;
Candalh, U ;
Rullier, A ;
Zerbib, F ;
Mégraud, F ;
Matysiak-Budnik, T ;
Heyman, M .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2005, 230 (10) :749-756
[28]   Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport [J].
Ménard, S ;
Candalh, C ;
Bambou, JC ;
Terpend, K ;
Cerf-Bensussan, N ;
Heyman, M .
GUT, 2004, 53 (06) :821-828
[29]   Comparison of the Immunomodulatory Properties of Three Probiotic Strains of Lactobacilli Using Complex Culture Systems: Prediction for In Vivo Efficacy [J].
Mileti, Erika ;
Matteoli, Gianluca ;
Iliev, Iliyan D. ;
Rescigno, Maria .
PLOS ONE, 2009, 4 (09)
[30]   Probiotic E-coli treatment mediates antimicrobial human β-defensin synthesis and fecal excretion in humans [J].
Moendel, M. ;
Schroeder, B. O. ;
Zimmermann, K. ;
Huber, H. ;
Nuding, S. ;
Beisner, J. ;
Fellermann, K. ;
Stange, E. F. ;
Wehkamp, J. .
MUCOSAL IMMUNOLOGY, 2009, 2 (02) :166-172